top of page

RESEARCH GRANTS

CURRENT RESEARCH GRANTS AND FUNDINGS RECEIVED

 

06/20-05/25  

Title: Accelerating Precision Medicine Translation: Development of the First Evidence-based Clinical Exceptional Responder Gene-Drug Sensitivity Resource for Cancer

Source:    Research Impact Fund

Role:  PC

Amount: HKD 14,280,000

 

06/20-03/21  

Postdoctoral Fellowship Scheme                         

Source:  Faculty of Medicine,  CUHK

Role: PI          

Amount: HKD 250,000  

 

02/20-01/21

Title:    A Multi-omics Discovery of Clinically Relevant Immune Cell Surface Markers in Head and Neck Squamous Cell Carcinoma (HNSCC)

Source: Endowment Fund Research, United College, CUHK

Role: PI          

Amount: HKD15,000

                     

09/19-04/20  

Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: InP/319/19    

Source: ITF Internship Prog             

Role: PI                      

Amount: HKD 156,940                     

 

03/19-02/23    

Title: qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents (#1R01CA229836-01A1)

Source: NIH (NCI) USA

Role: Co-I

Amount: USD 497,880/y budgeted 

 

06/19-05/24  

Title: Patient-Derived Preclinical Models for Translational Cancer Research: A Hong Kong-Based Biotechnology Centre for Genomic Medicine (R4017-18)

Source: Research Impact Fund, HK     

Role: Co-PI           

Amount: HKD 9,800,000

                      

06/18-05/21 

Title: RAC1 Genomic alterations drive Head and neck cancer progression (# 14168517)

Source: GRF, HK                           

Role: PI          

Amount: HKD 1,229,089

           

06/19-06/20  

Postdoctoral Fellowship Scheme                         

Source: Faculty of Medicine, CUHK         

Role: PI          

Amount: HKD 205,560

 

09/19-09/22 

Title: Overcoming chemoresistance in ovarian cancer by nanoscale co-delivery of imatinib and chemotherapeutic drugs “2017 HMRF Open Call Proposal” (#06173496)

Source:  HMRF, HK                       

Role: Co-A         

Amount: HKD 1,426,780                     

 

09/18–09/20 

Title: RAPTOR: Investigating the prognostic significance and therapeutic value of RAPTOR-ness for Head and Neck Cancer (HNC) (#15160691)

Source: HMRF, HK                     

Role: PI              

Amount: HKD 1,199,056

                     

02/19-01/20  

Title: A Multi-omics Approach for B cell Immune-Hotness Predictive of Patient Survival in Head and Neck Squamous Cell Carcinoma (HNSSC) (#CA11281)

Source: Endowment Fund Research, United College, CUHK    

Role: PI                

Amount: HKD 10,000

                    

05/18-04/20  

Title: Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329)    Source: UICP (50%-50%) ITF/ Lee’s Pharmaceutical (Hong Kong) Limited

Role: PI          

Amount: HKD 3,299,39 (HKD1.649.698 from ITF/ HKD1.649.698 from Lee’s)

 

02/19-04/20  

Title: Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: PiH/234/18            

Source: Post-doctoral Hub Programme / ITF                      

Role: PI                     

Amount: HKD 473,799.99

                    

09/18-04/20  

Title: Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: PiH/052/18

Source: Post-doctoral Hub Programme / ITF

Role: PI                      

Amount: HKD 626,355.75

 

09/18-04/20  

Drug Target Discovery for Anoikis-Resistance in Asian Head and Neck Cancer (HNC) (#UIM/329) Ref: InP/241/18    

Source: ITF Internship Prog             

Role: PI                      

Amount: HKD 338,709.67                     

 

07/18-7/21     

Novel Microneedle array loaded with Anti-PD-1-cisplatin-nanoparticles for Synergistic Cancer immune-chemotherapy (#17120718)                         

Source: GRF, HK                         

Role: Co-I           

Amount: HKD 703,899                     

 

10/16-09/20

Affordable Multi-gene mutation-drug matching for recurrent ovarian cancer patients in Hong Kong (#4441953)

Source: Hong Kong Cancer Fund, HK

Role: PI          

Amount: HKD 1,000,000

                        

01/18-12/20 

Incentive Scheme Award                                  

Source: Faculty of Medicine, CUHK, HK

Role: PI          

Amount: HKD 20,000

   

01/17-06/20 

Title: ALK/PIK3CA Genetic coupling: Implications for progression and Personalized therapy in Head and Neck Cancer (#17121616)   

Source: GRF, HK                          

Role: PI          

Amount: HKD 840,664

​

05/16-04/19

Title : Start-up Fund, School of Biomedical Sciences (SBS), CUHK   

Source: SBS, CUHK     

Role:PI

Amount: HKD 1,500,000                                              

 

PRIOR RESEARCH GRANTS RECEIVED
 

1999-2000

Title: University of Pittsburgh Graduate Training Program in breast cancer biology and therapy on “HER-2 ribozyme development”

Source: Department of Defense (DOD), USA

Role: Trainee

Amount: USD 1,000
 

12/99-8/00   

Title: University of Pittsburgh Graduate Training Program in Breast Cancer Biology and Therapy  On “HER-2 ribozyme development” 

Source: Department of Defense(DOD) USA   

Role: Trainee (100%)          

Amount: USD 1,000             

​

9/01-8/02     

Title: Post-doctoral fellowship, Lung Cancer  SPORE (Special Program of Research Excellence Grant) On “GRPR-mediated EGFR transactivation in NSCLC”

Source: NIH (NCI), USA       

Role: Post-doctoral Fellow    

Amount: USD 32,000

​

6/06-5/07     

Title: Direct Grant for Research (2005/06) “Molecular Targeting of STAT3 for Nasopharyngeal Carcinoma (NPC)”(#2005.2.011)

Source: CUHK, HK         

Role: PI       

Amount: HKD 41,400

  

1/06-12/07

Title: Endowment Fund Research Grant “Exploring the potential of active c-Met signaling in Nasopharyngeal carcinoma (NPC)”

Source: CUHK, HK          

Role: PI       

Amount: HKD 10,000

                 

6/07-5/08     

Title: Direct Grant for Research (2006/07) “Targeted inhibition of c-Met induces downregulation of another key Receptor Tyrosine Kinase, EGFR: Implication for treatment of metastatic Nasopharyngeal Carcinoma (NPC)” (# 2006.1.027)

Source: CUHK, HK                       

Role: PI        

Amount: HKD 78,250

     

4/07      

Title: Academic Equipment Grant for BENCHMARK®LT Automated Slide  Staining System

Source: CUHK, HK           

Role: PI             

Amount: HKD 598,000

      

1/07-12/08   

Title: Lee Hysan Foundation Research Grant Endowment Fund Research Grant  “Proteomics Changes Induced by DHMEQ,

a Novel NF-kB Inhibitor, in Nasopharyngeal Carcinoma (NPC)”

Source: CUHK, HK          

Role: PI      

Amount: HKD 30,000

​

5/08-4/09   

Title: Direct Grant for Research (2007/08)  “Biological Implication of Elevated Serum Hepatocyte Growth Factor (HGF) in the  Progression of Nasopharyngeal Carcinoma (NPC)”  (#2007.1.025) CUHK, HK          

Role:PI    

Amount: HKD 50,000

   

3/08-2/09     

Title: TAIHO Research Funding “Preclinical antitumor activity of TAS-106 in NPC” 

Source: TAHIO Pharmaceutical Co. Ltd., Japan

Role: PI      

Amount: USD 20,000

​

1/09-12/09   

Title: TAIHO Research Funding “Study on the involvement of TIGAR in  the antitumor activity of TAS-106 in NPC”               

Source: TAHIO Pharmaceutical Co. Ltd., Japan

Role: PI      

Amount: USD 10,000

    

3/08-2-09   

Title: Post-doctoral Fellowships Scheme for Intending Fellow (Application by PI)      

Source: CUHK, HK          

Role: PI      

Amount: HKD 129,072

 

1/08-12/09

Title: Lee Hysan Foundation Research Grant Endowment Fund Research Grant “TIGAR in Chemoresistance of Nasopharyngeal cancer (NPC)”

Source: CUHK, HK         

Role: PI            

Amount: HKD 18,000

 

3/09-3/10   

Title: Direct Grant for Research (2008/09)  “Brain-derived neurotrophic factor signaling and the invasiveness of Hepatocarcinoma cells” (#2008.1.101)

Source: CUHK, HK         

Role: Co-I      

Amount: HKD 30,000

 

6/09-5/10   

Title: Direct Grant for Research (2008/09) “A Novel Signaling Axis of STAT3/c-Met Regulation in Non-Small Cell Lung Cancer (NSCLC): A Direct Link between Two Important Players of Metastasis” (# 2008.1.025)

Source: CUHK, HK          

Role: PI      

Amount: HKD 62,000

​

3/10-3/11   

Title: Direct Grant for Research (2009/10) “A Novel Signaling Axis of TIGAR Induction by EGFR in Non-small Cell Lung Cancer (NSCLC)” (# 2009.1.012)

Source: CUHK, HK          

Role: PI    

Amount: HKD 35,000

​

3/10-3/11   

Title: Direct Grant for Research (2009/10) “The role of mTOR inhibition with nab-rapamycin in enhancing chemosensitivity of    

microtubule-stabilizing agent Abraxane in HCC” (# 2009.1.015)

Source: CUHK, HK       

Role: Co-I    

Amount: HKD 100,000

 

6/10-5/11  

Title: Research Grant from Novartis (MA, USA)   “PI3-K targeting in Nasopharyngeal cancer”         

Source: Novartis,USA      

Role: Co-I     

Amount: USD 30,000

 

1/07-12/10   

Title: Competitive Earmarked Research Grant  “Intrinsic Mechanism of c-Met induction as a point for therapeutic intervention for aggressive Nasopharyngeal Carcinoma (NPC)” (#471607)

Source: Research Grant Councils, HK Government, HK      

Role: PI                

Amount: HKD 1,049,224

     

10/08-9/11   

Title: Competitive Earmarked Research Grant “The role of STAT activation in regulating persistence of EBV infection in premalignant nasopharyngeal epithelial cell model” (#776608)

Source: Research Grant Councils, HK Government, HK     

Role: Co-I     

Amount: HKD 1,110,847

​

7/10-4/11   

Title: Competitive General Research Fund “Oncogenic Regulation of TIGAR by STAT3: A Mechanistic Study” (# 471810)

Source: Research Grant Councils, HK Government, HK       

Role: PI          

Amount: HKD 1,150,000

​

1/10-2/11    

Title: Preclinical evaluation of MK in NPC

Source: Merck & Co., Inc (MSD)      

Role: Co-I     

Amount: USD 10,000

​

2/08-12/11  

Merit Award for GRF Project  “The role of STAT activation in regulating persistence of EBV infection in premalignant

nasopharyngeal epithelial cell model” (HKU776608M)

Source: University of Hong Kong, HK    

Role: Co-I                

Amount: HKD 50,000

 

8/06-8/12     

Title: Li Ka Shing Institute for Health Sciences “Asian Cancer Studies-Cancer Drug Testing”

Source: CUHK, HK        

Role: Co-PI     

Amount: HKD 3,600,000

 

8/11-7/12    

Title: Head and Neck SPORE Developmental Research Award: “A Functional Genomic Platform to Identify Driver Mutations and

Effective Targeted Therapy for Head and Cancers”

Source: NIH (NCI), USA       

Role: PI    

Amount: USD 75,750

 

9/11-8/12  

Title: Genomic Analysis of Oncovirus-Associated Head and Neck Cancers in US and Chinese (US NIH-China NSFC)

Populations

Source: NIH, USA                      

Role: Co-I               

Amount: USD 100,000

 

12/10-12/12

Title: Clinical Trial Grant from Pfizer “RTK Targeting in Nasopharyngeal cancer patients (Clinical Trial)”

Source: Pfizer      

Role: Co-I   

Amount: USD 86,064.52

 

7/10-6/13   

Title: Competitive General Research Fund    “Oncogenic Regulation of TIGAR by              

STAT3: A Mechanistic Study” (# 471810)

Research Grant Councils, HK Government, HK         

Role: Co-I (5/11-6/13) PI (7/10-4/11)  

Amount: HKD 1,150,00

 

9/10-6/13    

Title: Research Incentive Scheme (award)         

Source: CUHK, HK                   

Role: PI         

Amount: HKD 20,000

 

7/11-6/13   

Title: Rare Head and Neck Malignancies for Therapeutic Target Identification for  Individualized Therapy    Pittsburgh Foundation        

Source:  Pittsburgh Foundation (The Patricia L. Knebel Fund)

Role: PI     

Amount: USD 10,000

​

05/12-11/13

Title: Anti-tumor mechanisms of PIK3CA inhibition (by BYL719) in preclinical HNSCC models

Source: Novartis, USA                   

Role: PI             

Amount: USD 55,597

​

06/12-12/13

Title: Anti-tumor mechanisms of PIK3CA inhibition (by BKM120) in preclinical HNSCC models

Source: Novartis, USA                   

Role: PI                   

Amount: USD 55,597    

​

09/12-10/13

Title: Testing Cancer Drug Combinations in 10 SCCHN Cell Lines (SPORE in Head Neck Cancer Developmental Research Program)

Source: NIH (NCI), USA      

Role: Co-PI              

Amount: USD 22,078

 

2/11-6/15    

Title: Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer Career Development Program

Source: NIH (NCI), USA      

Role: Co-I  

Amount: USD 59,328

      

06/15-05/16  

Title: Micro-PET Imaging for direct assessment of Drug-induced cell death in NPC models  

Source: NPC-AoE Project, HK              

Role: Co-I

Amount: HKD 150,000

                       

07/15-7/16   

Title: A pilot study to identify breast Cancer cell models for functional Genomics and Proteomics

Source: Strategic Theme Research, HKU               

Role: PI  

Amount: HKD 100,000

​

02/15-02/17

Title: A Precision therapeutic tool for head & Neck cancer 

Source: Applied Research, HKU     

Role: PI    

Amount: HKD 100,000

                   

07/14-06/16

Title: ALK inhibitors for Head & Neck Seed Funding for Cancer therapy 

Source: Basic Research, HKU   

Role: PI

Amount: HKD120,000

​

07/14-06/16

ALK inhibitors for Head & Neck Matching for Seed Cancer therapy 

Source: Funding for Basic Research, HKU

Role: PI

Amount: HKD120,000

 

​

bottom of page